MedTrace Logo

ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)

NCT04028349 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2021-05-12

No results posted yet for this study

Summary

An open-label, single arm phase II study of the candidate Ebola Vaccine Ad26.ZEBOV/MVA-BN®-Filo

Conditions

  • Ebola Virus Disease

Interventions

DRUG

Ad26.ZEBOV/MVA-BN-Filo

Candidate Ebola Vaccine

Sponsors & Collaborators

  • Epicentre, Mbarara, Uganda

    collaborator UNKNOWN

  • Janssen Pharmaceutica N.V., Belgium

    collaborator INDUSTRY

  • Coalition for Epidemic Preparedness Innovations

    collaborator OTHER

  • Epicentre, Paris, France.

    collaborator UNKNOWN

  • MRC/UVRI and LSHTM Uganda Research Unit

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2021-03-19
Completion
2021-03-19

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04028349 on ClinicalTrials.gov